Search results for "DMI"

showing 10 items of 7539 documents

Association of metformin administration with gut microbiome dysbiosis in healthy volunteers

2018

Background Metformin is a widely used first-line drug for treatment of type 2 diabetes. Despite its advantages, metformin has variable therapeutic effects, contraindications, and side effects. Here, for the very first time, we investigate the short-term effect of metformin on the composition of healthy human gut microbiota. Methods We used an exploratory longitudinal study design in which the first sample from an individual was the control for further samples. Eighteen healthy individuals were treated with metformin (2 × 850 mg) for 7 days. Stool samples were collected at three time points: prior to administration, 24 hours and 7 days after metformin administration. Taxonomic composition of…

0301 basic medicineMaleendocrine system diseasesPhysiologylcsh:MedicineType 2 diabetesGut floraPathology and Laboratory MedicineOpportunistic Pathogens0302 clinical medicineRNA Ribosomal 16SMedicine and Health SciencesLongitudinal Studieslcsh:ScienceData ManagementMultidisciplinarybiologydigestive oral and skin physiologyHigh-Throughput Nucleotide SequencingGenomicsHealthy VolunteersMetformin3. Good healthMetforminBacterial PathogensTolerabilityMedical MicrobiologyFemalePathogensmedicine.drugResearch ArticleMicrobial TaxonomyAdultDNA BacterialEscherichiaComputer and Information SciencesClostridiaceae030209 endocrinology & metabolismMicrobial GenomicsPlaceboDNA RibosomalMicrobiologyDrug Administration Schedule03 medical and health sciencesYoung AdultEnterobacteriaceaeAdverse ReactionsmedicineGeneticsHumansMicrobiomeMicrobial PathogensTaxonomyPharmacologyClostridiumBacteriabusiness.industryPeptostreptococcusTherapeutic effectlcsh:RGut BacteriaOrganismsBiology and Life SciencesSequence Analysis DNAmedicine.diseasebiology.organism_classificationGastrointestinal Microbiome030104 developmental biologyDysbiosislcsh:QMicrobiomebusinessDysbiosisPLOS ONE
researchProduct

The metabolism of mono-(2-ethylhexyl) phthalate (MEHP) and liver peroxisome proliferation in the hamster.

1988

This study has investigated the in vivo metabolism of mono-(2-ethylhexyl) phthalate (MEHP), the initial metabolite of di-(2-ethylhexyl) phthalate in mammals, and the hepatic peroxisome proliferation induced by this compound following multiple oral administration to hamsters. Hamsters received [14C]-MEHP, by gavage, at doses of 50 and 500 mg/kg body wt on each of three consecutive days. Urine was collected every 24 hours and metabolite profiles were determined using capillary gas-chromatography. Multiple high doses of MEHP (500 mg/kg) induced a change in the relative proportions of metabolites produced. As previously reported for the rat, metabolites derived from sequential ω-following by β…

0301 basic medicineMalemedicine.medical_specialtyHealth Toxicology and MutagenesisMetabolitePhthalic AcidsHamsterPeroxisome Proliferation010501 environmental sciencesToxicology01 natural sciencesMicrobodies03 medical and health scienceschemistry.chemical_compoundOral administrationInternal medicineCricetinaeDiethylhexyl PhthalatemedicineAnimals0105 earth and related environmental sciences030102 biochemistry & molecular biologyPublic Health Environmental and Occupational HealthPhthalateMetabolismPeroxisomeRatsEndocrinologychemistryLiverGlucuronideOxidation-ReductionToxicology and industrial health
researchProduct

Multidimensional Prognostic Index and pro-adrenomedullin plasma levels as mortality risk predictors in older patients hospitalized with community-acq…

2018

BACKGROUND: To evaluate the prognostic accuracy of proadrenomedullin (proADM) in comparison with and in addition to the Multidimensional Prognostic Index (MPI), a validated predictive tool for mortality derived from a comprehensive geriatric assessment (CGA) to predict one-month mortality risk in older patients hospitalized with community-acquired pneumonia (CAP). METHODS: All patients aged 65 years and older, consecutively admitted to an acute geriatric ward with a diagnosis of CAP from February to July 2012. At admission and at discharge they were submitted to a standard CGA in order to calculate MPI. Moreover, plasma samples were taken at baseline and after one, three and five days of ho…

0301 basic medicineMalemedicine.medical_specialtySeverity of Illness Index03 medical and health sciencesAdrenomedullin0302 clinical medicinePatient AdmissionOlder patientsCommunity-acquired pneumoniaPredictive Value of TestsRisk FactorsInternal medicineSeverity of illnessRisk of mortalityMedicineHumansProspective StudiesProtein PrecursorsProspective cohort studyGeriatric AssessmentAgedProportional Hazards ModelsAged 80 and overbusiness.industryProportional hazards modelGeneral MedicinePneumoniamedicine.diseasePrognosisPatient DischargeCommunity-Acquired InfectionsPneumonia030104 developmental biology030220 oncology & carcinogenesisPredictive value of testsFemalebusinessPanminerva medica
researchProduct

Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin.

1993

Since 1972, a large number of studies have shown that intravesical treatment with doxorubicin (adriamycin) is effective against carcinoma in situ and multiple papillary tumors. Furthermore, it significantly reduces the recurrence rate after transurethral resection. Its efficacy has been compared with that of Bacillus Calmette-Guerin (BCG), which is the only treatment accepted by the US Food and Drug Administration for therapy of carcinoma in situ (Tis). In more recent years, a few studies have been performed using intravesical epirubicin in the hope that different properties of the molecule might enhance the activity of the anthracyclines, but produce fewer and milder side-effects. After we…

0301 basic medicineMalemedicine.medical_specialtymedicine.medical_treatment030106 microbiologyUrologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawMedicineHumansPharmacology (medical)DoxorubicinEpirubicinPharmacologyChemotherapyUrinary bladderbusiness.industryCarcinoma in situCancermedicine.diseaseSurgeryInfectious Diseasesmedicine.anatomical_structureAdministration IntravesicalOncologyUrinary Bladder NeoplasmsDoxorubicin030220 oncology & carcinogenesisChemoprophylaxisbusinessCarcinoma in SituEpirubicinmedicine.drugJournal of chemotherapy (Florence, Italy)
researchProduct

Delivery of oral nutrition supplement in hospital: Evaluation of professional practices in evaluation of nutritional status and representations of ON…

2020

Journal non répertorié dans le JCR.; International audience; BACKGROUND: Nutritional evaluation and detection of malnutrition are based on criteria recommended by French health authorities. In practice, doctors do not always ensure strict implementation of the recommendations. The aim of this study is to evaluate professional practices in France regarding nutritional follow-up on arrival, during and after the hospitalization of inpatients who have oral nutritional supplements (ONS) prescribed and to discuss how ONS are seen by medical staff and patients. METHODS: A prospective study including patients consecutively admitted to digestive surgery and endocrinology units of the Dijon universit…

0301 basic medicineMalerepresentationEndocrinology Diabetes and MetabolismAdministration Oral[SHS]Humanities and Social Sciences0302 clinical medicineWeight lossProspective StudiesProspective cohort studyComputingMilieux_MISCELLANEOUS2. Zero hungerAged 80 and overNutrition and DieteticsNutritional statusProfessional PracticeMiddle AgedUniversity hospital3. Good healthHospitalizationCaregiversoral nutritional supplementsFemaleFrance[SHS] Humanities and Social Sciencesmedicine.symptomAdultmedicine.medical_specialty[SHS.INFO]Humanities and Social Sciences/Library and information sciencesNutritional Status030209 endocrinology & metabolism[SHS.INFO] Humanities and Social Sciences/Library and information sciences03 medical and health sciencesYoung AdultWeight LossmedicineHumansIn patientAged030109 nutrition & dieteticsbusiness.industryMalnutritionAnthropometryLength of Staymedicine.diseaseMalnutritionNutrition AssessmentFamily medicineDietary Supplementsbusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBody mass indexFollow-Up Studies
researchProduct

Signature of Circulating Biomarkers in Recurrent Non-Infectious Anterior Uveitis. Immunomodulatory Effects of DHA-Triglyceride. A Pilot Study

2021

The purpose of this study was to identify circulating biomarkers of recurrent non-infectious anterior uveitis (NIAU), and to address the anti-inflammatory effects of triglyceride containing docosahexaenoic acid (DHA-TG). A prospective multicenter study was conducted in 72 participants distributed into: patients diagnosed with recurrent NIAU in the quiescence stage (uveitis group (UG)

0301 basic medicineMedicine (General)medicine.medical_specialtyClinical BiochemistryÀcids grassos omega-3GastroenterologyArticlerecurrent anterior non-infectious uveitisUveitis03 medical and health scienceschemistry.chemical_compoundR5-9200302 clinical medicineOral administrationInternal medicineOmega-3 fatty acidsMedicineTriglicèridsStage (cooking)Triglyceridesomega-3 fatty acidsTriglyceridebusiness.industryInterleukintriglyceride of docosahexaenoic acidmedicine.diseasecytokinesCirculating biomarkers030104 developmental biologychemistryDocosahexaenoic acidUveïtis030221 ophthalmology & optometryTumor necrosis factor alphabusinessUveitisDiagnostics
researchProduct

Mucoadhesive solid lipid microparticles for controlled release of a corticosteroid in the chronic obstructive pulmonary disease treatment.

2017

Therapeutic efficacy of inhaled drugs is limited by rapid clearance from the site of action due to absorption into systemic circulation or metabolic degradation by alveolar macrophages. Drug delivery systems offer new solutions to clinical problems especially in the treatment of pulmonary diseases. In particular, Solid Lipid Microparticles (SLM) in the range of 3-5 µm are suggested as systems for delivery of therapeutics to the lung as, because of their size, they are able to deposit into secondary bronchi, avoiding systemic absorption typical of alveolar regions. Here, we describe two novel different SLMs prepared with chitosan and alginate for sustained release of fluticasone propionate (…

0301 basic medicineMedicine (miscellaneous)Biocompatible Materials02 engineering and technologyPharmacologymedicine.disease_causeChitosanPulmonary Disease Chronic Obstructivechemistry.chemical_compoundDrug StabilityGlucuronic AcidAdrenal Cortex HormonesMucoadhesive Solid Lipid Nanoparticles (SLMs);Aerodynamic diameter;Chronic obstructive pulmonary disease (COPD)General Materials Sciencechronic obstructive pulmonary disease (COPD)LungChromatography High Pressure LiquidDrug CarriersHexuronic Acidsaerodynamic diameter; chronic obstructive pulmonary disease (COPD); mucoadhesive solid lipid microparticles (SLMs)021001 nanoscience & nanotechnologyLipidsControlled releasemucoadhesive solid lipid microparticles (SLMs)Microspheresmedicine.anatomical_structureDrug deliveryCorticosteroid0210 nano-technologymedicine.drugBiocompatibilityAlginatesCell SurvivalSurface Propertiesmedicine.drug_classBiomedical EngineeringBioengineeringDevelopmentFluticasone propionate03 medical and health sciencesAdministration InhalationmedicineHumansParticle Sizeaerodynamic diameterChitosanLungbusiness.industryEpithelial CellsDrug LiberationOxidative Stress030104 developmental biologychemistryDelayed-Action PreparationsImmunologyMicroscopy Electron ScanningFluticasonebusinessOxidative stress
researchProduct

Milk and blood biomarkers associated to the clinical efficacy of a probiotic for the treatment of infectious mastitis

2016

Previous studies have shown the efficacy of oral administration of selected lactobacilli strains to treat mastitis. The objective of this study was to find microbiological, biochemical and/or immunological biomarkers of the probiotic effect. Women with (n=23) and without (n=8) symptoms of mastitis received three daily doses (109 cfu) of Lactobacillus salivarius PS2 for 21 days. Samples of milk, blood and urine were collected before and after the probiotic intervention, and screened for a wide spectrum of microbiological, biochemical and immunological parameters. In the mastitis group, L. salivarius PS2 intake led to a reduction in milk bacterial counts, milk and blood leukocyte counts and i…

0301 basic medicineMicrobiology (medical)UrinalysisAdministration OralMastitisUrineUrinalysisMicrobiologylaw.invention03 medical and health sciencesProbioticOral administrationlawHumansMedicineMilk Humanbiologymedicine.diagnostic_testbusiness.industryProbioticsLactobacillus salivariusfood and beveragesInterleukinbiology.organism_classificationmedicine.diseaseLactobacillus salivariusMastitisTreatment OutcomeBloodMilk030104 developmental biologyImmunologyLigilactobacillus salivariusbiology.proteinFemaleAntibodybusinessBiomarkersBlood Chemical AnalysisBeneficial Microbes
researchProduct

The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives

2021

INTRODUCTION: The COVID-19 pandemic has dramatically challenged the national health systems worldwide in the last months. Dalbavancin is a novel antibiotic with a long plasmatic half-life and simplified weekly administration regimens, thus representing a promising option for the outpatient treatment of Gram-positive infections and the early discharge of hospitalized patients. Dalbavancin is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Many preliminary data seem to support its use in other indications, such as osteomyelitis, prosthetic joint infections, and infective endocarditis. AREAS COVERED: A search in the literature using validated keyword…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)medicine.drug_classProsthetic joint030106 microbiologyAntibioticsGram-Positive Bacterial InfectionABSSSIsMicrobiologyDrug Administration Scheduleosteomyelitis.endocarditi03 medical and health sciencesABSSSIs; COVID-19; dalbavancin; endocarditis; Gram-positive; long-acting; osteomyelitisGram-positive0302 clinical medicineVirologyPandemicAnti-Bacterial AgentmedicineAmbulatory CareAnimalsHumans030212 general & internal medicineIntensive care medicineGram-Positive Bacterial Infectionsbusiness.industryAnimalOsteomyelitisDalbavancinCOVID-19osteomyelitisSkin Diseases Bacteriallong-actingABSSSImedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesInfective endocarditisSkin structureendocarditisosteomyelitiTeicoplaninbusinessdalbavancinHuman
researchProduct

Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and…

2019

Abstract Background The combination of cisplatin, 5-fluorouracil (5-FU) and cetuximab (PFC) is the reference first-line treatment for recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). We analysed whether treatment intensification by the addition of docetaxel to PFC improved efficacy in R/M SCCHN. Methods A total of 180 patients with R/M SCCHN (1:1) were assigned to receive either cisplatin (40 mg/m2), docetaxel (40 mg/m2) and 5-FU (2000 mg/m2) at days 1 and 8 and cetuximab (400/250 mg/m2) at days 1, 8 and 15 (DPFC) or standard cisplatin (100 mg/m2) at day 1, 5-FU (1000 mg/m2) at days 1–4 and cetuximab (400/250 mg/m2) at days 1, 8 and 15 (PFC). Chemotherapy was…

0301 basic medicineOncologyAdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentMedizinCetuximabDocetaxelDisease-Free SurvivalDrug Administration Schedule03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesAgedCisplatinChemotherapyCetuximabbusiness.industrySquamous Cell Carcinoma of Head and NeckHead and neck cancerHazard ratioMiddle AgedInterim analysismedicine.disease030104 developmental biologyOncologyDocetaxelFluorouracil030220 oncology & carcinogenesisFemaleFluorouracilCisplatinbusinessmedicine.drug
researchProduct